Development and validation of a stability-indicating rp-hplc method for simultaneous estimation of rilpivirine and cabotegravir in dosage forms
Keywords:
Rilpivirine, Cabotegravir, RP-HPLC, Method Validation, Stability-IndicatingAbstract
A simple, accurate, and precise method for the simultaneous estimation of Rilpivirine and Cabotegravir in pharmaceutical dosage forms was developed and validated using RP-HPLC. The analysis was performed on a Sunfire C18 column (150 mm x 4.6 mm, 5 µm) with a mobile phase of 0.1% orthophosphoric acid and acetonitrile in a 60:40 ratio at a flow rate of 1.0 mL/min. Retention times for Rilpivirine and Cabotegravir were 2.174 min and 2.815 min, respectively. Method validation demonstrated linearity, accuracy, and precision, with %RSD values below 2%, recovery rates of 99.51%-100.35%, and LOD/LOQ values of 0.38 µg/mL/1.15 µg/mL for Rilpivirine and 0.06 µg/mL/0.19 µg/mL for Cabotegravir. This stability-indicating method is efficient and economical for routine quality control in pharmaceutical industries.